• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Emergence of KPC-31, a KPC-3 Variant Associated with Ceftazidime-Avibactam Resistance, in an Extensively Drug-Resistant ST235 Pseudomonas aeruginosa Clinical Isolate.产 KPC-31 碳青霉烯酶，一种与头孢他啶-阿维巴坦耐药相关的 KPC-3 变体，在广泛耐药的 ST235 铜绿假单胞菌临床分离株中出现。
Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0064822. doi: 10.1128/aac.00648-22. Epub 2022 Oct 26.
2
Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.产生赋予对头孢他啶-阿维巴坦耐药性的 KPC-2 突变的菌株中，沃博巴坦的效力比阿维巴坦的效力受影响更小。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01936-19.
3
Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.在治疗期间，通过序列类型39的产KPC-2肺炎克雷伯菌中不同的基因组适应性变化出现了对头孢他啶-阿维巴坦的耐药性。
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):219-224. doi: 10.1007/s10096-020-04000-9. Epub 2020 Jul 30.
4
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.
5
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
6
In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.产 KPC 肺炎克雷伯菌在头孢他啶/阿维巴坦治疗期间耐药亚群的体内进化。
J Antimicrob Chemother. 2018 Jun 1;73(6):1525-1529. doi: 10.1093/jac/dky082.
7
Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.体内产 KPC-3 肺炎克雷伯菌出现对头孢他啶/阿维巴坦的耐药性。
J Antimicrob Chemother. 2019 Nov 1;74(11):3211-3216. doi: 10.1093/jac/dkz330.
8
In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.在接受头孢他啶/阿维巴坦治疗的患者分离出的肺炎克雷伯菌中对KPC-94和KPC-95进行体内筛选。
Int J Antimicrob Agents. 2022 Feb;59(2):106524. doi: 10.1016/j.ijantimicag.2022.106524. Epub 2022 Jan 14.
9
In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies.产碳青霉烯酶肺炎克雷伯菌在接受头孢他啶/阿维巴坦治疗后体内出现头孢地尔和头孢他啶/阿维巴坦交叉耐药性。
Diagn Microbiol Infect Dis. 2024 Sep;110(1):116372. doi: 10.1016/j.diagmicrobio.2024.116372. Epub 2024 May 21.
10
A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring Isolated in New York City.一株耐头孢他啶-阿维巴坦、碳青霉烯类敏感的肺炎克雷伯菌的分离与鉴定：来自纽约市的报告。
mSphere. 2020 Aug 26;5(4):e00775-20. doi: 10.1128/mSphere.00775-20.

引用本文的文献

1
Diverse modes of ceftazidime/avibactam resistance acquisition in carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa from a Chinese intensive care unit.来自中国重症监护病房的耐碳青霉烯类肺炎克雷伯菌和铜绿假单胞菌中获得头孢他啶/阿维巴坦耐药性的多种模式
Ann Clin Microbiol Antimicrob. 2025 May 30;24(1):35. doi: 10.1186/s12941-025-00800-z.
2
Mechanisms leading to ceftazidime/avibactam resistance development during treatment of GES-5-producing infections.在治疗产 GES-5 的感染期间导致头孢他啶/阿维巴坦耐药性发展的机制。
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0116424. doi: 10.1128/aac.01164-24. Epub 2024 Oct 21.
3
Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa.染色体编码耐药机制和可转移β-内酰胺酶对头孢地尔的活性及新型β-内酰胺/β-内酰胺酶抑制剂组合对铜绿假单胞菌的影响。
J Antimicrob Chemother. 2024 Oct 1;79(10):2591-2597. doi: 10.1093/jac/dkae263.
4
First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197.哥伦比亚首次报道产碳青霉烯酶变种导致头孢他啶-阿维巴坦耐药：引入 KPC-197。
Microbiol Spectr. 2024 Jun 4;12(6):e0410523. doi: 10.1128/spectrum.04105-23. Epub 2024 May 3.
5
The balance between antibiotic resistance and fitness/virulence in : an update on basic knowledge and fundamental research.抗生素耐药性与适应性/毒力之间的平衡：基础知识与基础研究的最新进展
Front Microbiol. 2023 Sep 28;14:1270999. doi: 10.3389/fmicb.2023.1270999. eCollection 2023.
6
Worldwide Dissemination of Gene by Novel Mobilization Platforms in : A Systematic Review.新型移动平台介导的基因在全球的传播：一项系统综述
Antibiotics (Basel). 2023 Mar 28;12(4):658. doi: 10.3390/antibiotics12040658.

本文引用的文献

1
Emergence of a KPC-90 Variant that Confers Resistance to Ceftazidime-Avibactam in an ST463 Carbapenem-Resistant Pseudomonas aeruginosa Strain.ST463 型碳青霉烯类耐药铜绿假单胞菌中出现对头孢他啶-阿维巴坦耐药的 KPC-90 变体。
Microbiol Spectr. 2022 Feb 23;10(1):e0186921. doi: 10.1128/spectrum.01869-21. Epub 2022 Jan 12.
2
Interplay between Klebsiella pneumoniae producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report.高产碳青霉烯酶肺炎克雷伯菌 KPC-31 和 KPC-3 在高剂量美罗培南治疗下相互作用：一例报告。
Eur J Clin Microbiol Infect Dis. 2022 Mar;41(3):495-500. doi: 10.1007/s10096-021-04388-y. Epub 2022 Jan 6.
3
Ceftazidime/avibactam resistance is associated with different mechanisms in KPC-producing Klebsiella pneumoniae strains.在产KPC的肺炎克雷伯菌菌株中，头孢他啶/阿维巴坦耐药性与不同机制相关。
Acta Microbiol Immunol Hung. 2021 Nov 5. doi: 10.1556/030.2021.01626.
4
Evolution of GES β-Lactamases Driven by Ceftazidime/Avibactam Treatment of Pseudomonas aeruginosa Infections.耐头孢他啶/阿维巴坦治疗铜绿假单胞菌感染的 GES β-内酰胺酶的演变。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0098621. doi: 10.1128/AAC.00986-21.
5
Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis.通过全基因组序列耐药组分析预测铜绿假单胞菌的药敏表型
Clin Microbiol Infect. 2021 Nov;27(11):1631-1637. doi: 10.1016/j.cmi.2021.05.011. Epub 2021 May 18.
6
Carbapenemase detection testing in the era of ceftazidime/avibactam-resistant KPC-producing Enterobacterales: A 2-year experience.碳青霉烯酶检测试验在产头孢他啶/阿维巴坦耐药 KPC 肠杆菌科中的应用：为期 2 年的经验。
J Glob Antimicrob Resist. 2021 Mar;24:411-414. doi: 10.1016/j.jgar.2021.02.008. Epub 2021 Feb 20.
7
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections.多重耐药和广泛耐药铜绿假单胞菌感染的流行病学和治疗。
Clin Microbiol Rev. 2019 Aug 28;32(4). doi: 10.1128/CMR.00031-19. Print 2019 Sep 18.
8
Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.美罗培南/阿维巴坦耐药的铜绿假单胞菌临床分离株中 MexAB-OprM 过度表达及外排调节蛋白、青霉素结合蛋白和伴侣蛋白突变的联合作用。
J Antimicrob Chemother. 2019 Sep 1;74(9):2588-2595. doi: 10.1093/jac/dkz243.
9
Performance of "RESIST-3 O.K.N. K-SeT" immunochromatographic assay for the detection of OXA-48 like, KPC, and NDM carbapenemases in Klebsiella pneumoniae in Turkey.“RESIST-3 O.K.N. K-SeT”免疫层析法在土耳其检测肺炎克雷伯菌中OXA-48样、KPC和NDM碳青霉烯酶的性能
Braz J Microbiol. 2018 Oct-Dec;49(4):885-890. doi: 10.1016/j.bjm.2018.02.002. Epub 2018 Mar 1.
10
Global emergence of the widespread Pseudomonas aeruginosa ST235 clone.广泛流行的铜绿假单胞菌 ST235 克隆在全球的出现。
Clin Microbiol Infect. 2018 Mar;24(3):258-266. doi: 10.1016/j.cmi.2017.06.018. Epub 2017 Jun 23.

产 KPC-31 碳青霉烯酶，一种与头孢他啶-阿维巴坦耐药相关的 KPC-3 变体，在广泛耐药的 ST235 铜绿假单胞菌临床分离株中出现。

Emergence of KPC-31, a KPC-3 Variant Associated with Ceftazidime-Avibactam Resistance, in an Extensively Drug-Resistant ST235 Pseudomonas aeruginosa Clinical Isolate.

机构信息

Servicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas (INEI) - ANLIS "Dr. Carlos G. Malbrán", Buenos Aires, Argentina.

Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.

出版信息

Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0064822. doi: 10.1128/aac.00648-22. Epub 2022 Oct 26.

DOI:10.1128/aac.00648-22
PMID:36286541
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9664854/
Abstract

A ceftazidime-avibactam-resistant KPC-producing Pseudomonas aeruginosa strain was isolated in Argentina from a tracheal aspirate. The patient was treated with ceftazidime-avibactam in combination with other agents for 130 days. Whole-genome sequencing of P. aeruginosa identified a D179Y substitution in the Ω loop of KPC-3, corresponding to KPC-31, integrated at the chromosome. The strain belonged to the sequence type 235/O11 (ST235/O11) high-risk clone. Evaluation of carbapenemase detection assays most used by clinical laboratories failed to identify the isolate as a KPC producer.

摘要

阿根廷从一名气管抽吸患者的标本中分离出一株产头孢他啶-阿维巴坦耐药 KPC 的铜绿假单胞菌。该患者接受头孢他啶-阿维巴坦联合其他药物治疗 130 天。对铜绿假单胞菌的全基因组测序发现 KPC-3 的Ω环中的 D179Y 取代，对应于整合在染色体上的 KPC-31。该菌株属于序列型 235/O11（ST235/O11）高危克隆。对临床实验室最常使用的碳青霉烯酶检测方法进行评估未能鉴定该分离株为 KPC 产生菌。